Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
OncoTherapy Science, Inc. (4564.T)
Kawasaki, TK, JP
OncoTherapy Science, Inc. engages in research and development of anti-body drugs; and the genome analysis of cancer, liquid biopsy, and development of new immunotherapy in Japan. Its development pipeline includes OTS167, a small molecular compound that targets the maternal embryonic leucine zipper kinase inhibitor that is in Phase I/II clinical trials for the treatment of acute myeloid leukemia, as well as in Phase I clinical trials for the treatment of breast cancer; and OTS964, a small molecule TOPK inhibitor currently under non-clinical stage. The company’s pipeline also comprises cancer peptide vaccines, including S-588410, which completed Phase III clinical trials for the treatment esophageal cancer, as well as Phase II clinical trials for the treatment of bladder cancer; S-488210, which is in Phase I/II clinical trials for the treatment of head and neck cancer; S-588210, which is in Phase I clinical trials for the treatment of solid tumor; and OTSGC-A24, currently in Phase I clinical trials for the treatment of gastric cancer. In addition, it is developing antibody drugs consisting of OTSA101, which is in Phase I clinical trials for synovial sarcoma; and an anti-amyloid beta peptide antibody that completed Phase I clinical trials for Alzheimer’s disease. OncoTherapy Science, Inc. was incorporated in 2001 and is headquartered in Kawasaki, Japan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -12.50% | -12.50% | +0.00% | -12.50% | +0.00% | -12.50% | -44.74% | -80.37% | -93.33% | -95.53% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+7.8% ★ Q1'26: +13.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+11.2% Q1'26: +30.6% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-114.7% Q1'26: +0.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-100.2% Q1'26: -71.7% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,539.4% Q1'26: -1,149.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+25.7% Q1'26: +83.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2021 actual |
|---|---|---|---|---|---|---|---|
| Revenue |
769.96M
est: 800.00M (-3.8%)
|
266.90M
est: 1.00B (-73.3%)
|
286.67M
est: 260.00M (+10.3%)
|
211.25M
est: 300.00M (-29.6%)
|
280.59M
est: 200.00M (+40.3%)
|
316.22M
est: 200.00M (+58.1%)
|
332.48M
est: 200.00M (+66.2%)
|
| EBITDA |
-1.86B
est: -793.81M (-133.9%)
|
-2.86B
est: -992.26M (-187.8%)
|
-2.92B
est: -257.99M (-1,029.9%)
|
-2.84B
est: -297.68M (-854.0%)
|
-2.56B
est: -198.45M (-1,191.5%)
|
-2.15B
est: -198.45M (-983.4%)
|
-1.59B
est: -198.45M (-700.7%)
|
| EBIT |
-1.96B
est: -796.07M (-146.5%)
|
-2.98B
est: -995.08M (-199.6%)
|
-3.00B
est: -258.72M (-1,061.2%)
|
-2.99B
est: -298.52M (-901.1%)
|
-2.95B
est: -199.02M (-1,384.2%)
|
-2.19B
est: -199.02M (-1,000.2%)
|
-1.64B
est: -199.02M (-723.0%)
|
| Net Income |
-1.33B
est: -2.48B (+46.2%)
|
-2.79B
est: -3.55B (+21.5%)
|
-3.00B
est: -5.51B (+45.5%)
|
-2.85B
est: -5.33B (+46.5%)
|
-2.93B
est: 5.33B (-155.1%)
|
-2.24B
est: 5.33B (-142.0%)
|
-1.56B
est: 5.33B (-129.3%)
|
| SGA |
338.80M
est: 389.20M (-13.0%)
|
364.06M
est: 486.50M (-25.2%)
|
352.74M
est: 126.49M (+178.9%)
|
267.95M
est: 145.95M (+83.6%)
|
407.72M
est: 97.30M (+319.0%)
|
397.38M
est: 97.30M (+308.4%)
|
281.80M
est: 97.30M (+189.6%)
|
| EPS |
-9.09
est: -9.50 (+4.3%)
|
-18.97
est: -13.60 (-39.5%)
|
-20.42
est: -21.10 (+3.2%)
|
-19.39
est: -20.40 (+5.0%)
|
-19.90
est: 20.40 (-197.5%)
|
-13.73
est: 20.40 (-167.3%)
|
-8.86
est: 20.40 (-143.4%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 2/5 |
| 2026-05-01 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 2/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hatsuo Kato | Executive Chairman | — | male |
| Jae-Hyun Park | Chief Scientific Officer, GM of Management Headquarters & Director | — | male |
| Junichi Shimada | President, Chief Executive Officer & Director | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4564.T
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
